NTMir’s mission is to save and improve lives through research, education, early detection, and improved treatments for people with pulmonary nontuberculous mycobacterial (NTM) disease.

Latest News

View More

FDA Advisory Committee Meeting on Inhaled Liposomal Amikacin

The U.S. Food & Drug Administration (FDA) has posted a Federal Register Notice announcing the upcoming Anti-Microbial Advisory Committee Meeting for Insmed’s inhaled liposomal amikacin. The committee...
Read More

FDA Workshop on Bronchiectasis Drug Development

The Food and Drug Administration is convening a public workshop titled “Development of Inhaled Antibacterial Drugs for Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis” on Wednesday, June 27th...
Read More

ATS/PAR Meet the Experts

The American Thoracic Society Public Advisory Roundtable (ATS/PAR) is proud to present their 12th Annual “Meet the Experts” Patient/Family Forum at the Manchester Grand Hyatt Hotel on...
Read More

Corporate Sponsor

Stay Informed

Sign up for NTMir's news releases